The development of new anticancer agents is one of the most rapidly changing aspects of cancer research. Investigational New Drugs provides a forum for the rapid dissemination of information on new anticancer agents. The papers published are of interest to the medical chemist, toxicologist, pharmacist, pharmacologist, biostatistician and clinical oncologist. Investigational New Drugs provides the fastest possible publication of new discoveries and results for the whole community of scientists developing anticancer agents.

Each issue contains original articles dealing with anticancer drug development. Other sections are devoted to invited review articles and letters to the editor. The journal also affords the opportunity to publish the proceedings of special workshops and symposia devoted to the development of new anticancer agents. Provided they add to the understanding of the investigational agents, the journal is not adverse to publishing clinical trials with negative results.

Investigational New Drugs cuts across all the usual lines or subdisciplines, providing a locus for the presentation of relevant investigations and the discussion of critical questions appropriate to the entire field of new anticancer drug development.

100% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again

Journal information

Editor-in-Chief
  • Eric K. Rowinsky
Publishing model
Hybrid. Open Access options available

Journal metrics

3.525 (2019)
Impact factor
3.384 (2019)
Five year impact factor
20 days
Submission to first decision
66 days
Submission to acceptance
207,125 (2019)
Downloads

Latest articles

Journal updates

  • COVID-19 and impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times.  Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

View all updates

Subscribe

eJournal
$99.00
Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access with complete access to all articles
  • Downloadable in PDF format
  • Subscription expires 12/31/2020

About this journal

Electronic ISSN
1573-0646
Print ISSN
0167-6997
Abstracted and indexed in
  1. BIOSIS
  2. Biological Abstracts
  3. CNKI
  4. Chemical Abstracts Service (CAS)
  5. Current Contents/ Life Sciences
  6. Current Contents/Clinical Medicine
  7. Dimensions
  8. EBSCO Biomedical Reference Collection
  9. EBSCO CINAHL
  10. EBSCO Discovery Service
  11. EMBASE
  12. Elsevier Biobase
  13. Google Scholar
  14. Institute of Scientific and Technical Information of China
  15. Japanese Science and Technology Agency (JST)
  16. Journal Citation Reports/Science Edition
  17. Medline
  18. Naver
  19. OCLC WorldCat Discovery Service
  20. Pathway Studio
  21. ProQuest ABI/INFORM
  22. ProQuest Agricultural & Environmental Science Database
  23. ProQuest Biological Science Database
  24. ProQuest Biotechnology Research Abstracts
  25. ProQuest Business Premium Collection
  26. ProQuest Central
  27. ProQuest Consumer Health
  28. ProQuest Engineering
  29. ProQuest Environmental Science
  30. ProQuest Health & Medical Collection
  31. ProQuest Health Research Premium Collection
  32. ProQuest Materials Science and Engineering Database
  33. ProQuest Medical Database
  34. ProQuest Natural Science Collection
  35. ProQuest Nursing & Allied Health Database
  36. ProQuest Pharma Collection
  37. ProQuest SciTech Premium Collection
  38. ProQuest Technology Collection
  39. ProQuest-ExLibris Primo
  40. ProQuest-ExLibris Summon
  41. Reaxys
  42. SCImago
  43. SCOPUS
  44. Science Citation Index
  45. Science Citation Index Expanded (SciSearch)
  46. Semantic Scholar
  47. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Springer Science+Business Media, LLC, part of Springer Nature